Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PetMed (PETS) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in PetMed and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Nov. 01, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recog ...

Seasoned corporate director brings extensive expertise in audit, accounting, and internal controls Fourth independent director to join the board since 2024 DELRAY BEACH, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company”), today announced the appointment, effective immediately, of James LaCamp to the Company’s Board of Directors (the “Board”), and effective October 30, Mr. LaCamp will become Chair of the Audit Committee ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PetMed (PETS) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in PetMed and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recog ...

根据您提供的任务要求和关键点内容，当前的关键点数量较少，且主要围绕财报发布和报告性质本身。以下是根据现有信息进行的严格分组： 财报发布与报告基础信息 - 公司于2025年10月14日宣布了截至2025年3月31日的财年财务业绩[5] - 公司参考了非GAAP财务信息，并提供了与最接近的可比GAAP财务指标的对照表[7] 前瞻性陈述说明 - 本8-K报告及所附新闻稿包含有关前瞻性陈述的警示性说明[10]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR For the transition period from __________ to __________ Commission File Number 000-28827 _____________________________________________________________________ PETMED EXPRESS, INC. (Exact name of registrant as ...

DELRAY BEACH, Fla., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today filed with the Securities and Exchange Commission (SEC) its Annual Report on Form 10-K for the fiscal year ended March 31, 2025. Fiscal 2025 Financial Highlights Net sales of $227.0 million for fiscal 2025, below the preliminary estimated range of $231.6 million to $233.6 million, primarily due to the previously announced restatement of promotional sales ...

调查背景 - 律师事务所Frank R Cruz正在对PetMed Express Inc进行调查 代表可能因公司行为而遭受损失的投资者 [1] - 调查涉及公司可能违反联邦证券法的行为 [1] 调查触发事件 - 公司于2025年6月10日披露将延迟某项未明确说明的事务 [1]

SAN FRANCISCO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Investors in PetMed Express (NASDAQ: PETS) have seen the price of their shares steadily decline by about 26% since June 16, 2025, when the company announced it would not timely file its annual financial statements for its year ended March 31, 2025. Later disclosures reveal serious additional company problems. The developments and severe market reaction have prompted national shareholders rights firm Hagens Berman to open an investigation into whether PetMed m ...

公司事件 - PetMed Express因涉嫌违反证券法正接受Block & Leviton调查 投资者可能通过法律途径追回损失 [1][4] - 公司两次推迟2025年第四季度及年度财务报告发布 首次延迟于6月10日 第二次于7月1日 原因包括收入确认问题的内部调查 [2] - 8月12日公司CEO与CFO辞职 消息导致股价单日下跌近30% [2] 投资者参与条件 - 持有PetMed Express普通股且遭受亏损的投资者均符合参与调查资格 无论是否已出售持股 [3] - 潜在举报者若掌握非公开信息可协助调查 通过SEC举报人计划最高可获得追回金额30%的奖励 [6] 法律机构背景 - Block & Leviton被公认为证券集体诉讼领域领先律所 曾为投资者追回数十亿美元损失 [7] - 该律所代表多家顶级机构投资者利益 通过联邦法院主动诉讼为客户争取重大赔偿 [7]

高管变动 - 公司首席执行官Sandra Campos和首席财务官Robyn D'Elia已辞职[1] - 董事会主席Leslie C G Campbell担任临时首席执行官 首席会计官Douglas Krulik担任临时首席财务官[2] - 公司已开始寻找新的首席执行官和首席财务官[2] 离职协议 - 两位高管签署了离职协议 将获得13个月基本工资的遣散费[3] - 部分未归属的限制性股票单位将加速归属[3] - 两位高管同意在未来3个月内根据需要提供咨询服务[3] 董事会调整 - Sandra Campos同时辞去董事会成员职务 董事会成员减少至5人[4] - Leslie C G Campbell辞去审计委员会和薪酬与人力资本委员会职务[4] - Justin Mennen被任命为董事会首席独立董事[4] - Peter Batushansky被任命为审计委员会主席 Leah Solivan被任命为薪酬与人力资本委员会主席[4] 公司背景 - 公司成立于1996年 是直接面向消费者的宠物医疗保健行业先驱[5] - 公司拥有全美50个州的在线药房执照[5] - 提供品牌药 仿制药 复合药物和宠物营养补充剂等产品[5]